Price
No data yet.
Social Signal Score
Revenue
$7.48B+46.70%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gavin Wood
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 16,907
- Beta
- 0.53
- Country
- DK
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.39
Financials
Revenue
$7.48B+46.7%Net Income
$1.49B+14.0%EBITDA
$2.31B+24.7%Free Cash Flow
$1.49B-10.7%EPS (diluted)
$0.65+6.6%Shares Outstanding (diluted)
2.25B+5.9%Operating Expenses
$3.06BCash & Debt
$817.04MReturn of Capital
$1.16BDividend per Share
$0.08Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $26.25B | $3.42B | $1.52 |
| 2024 | $27.03B | $5.05B | $2.25 |
| 2023 | $24.50B | $4.78B | $2.22 |
| 2022 | $22.58B | $4.71B | $2.22 |
| 2021 | $19.43B | $4.83B | $2.27 |
| 2020 | $18.54B | $4.20B | $1.97 |
| 2019 | $17.94B | $3.87B | $1.82 |
| 2018 | $16.45B | $3.85B | $1.81 |
| 2017 | $15.53B | $3.80B | $1.79 |
| 2016 | $14.68B | $3.14B | $1.49 |
| 2015 | $13.91B | $899.00M | $0.43 |
| 2014 | $12.43B | $2.39B | $1.13 |
| 2013 | $11.63B | $2.71B | $1.29 |
| 2012 | $11.02B | $2.19B | $1.04 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CLPBY's reported EPS growth of 3.0% a year over 13 years.
- EPS in 5 years
- $1.76
- Implied price
- $63.42
- Return from $6.79
- 56.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $31.53 — today's price is already 78.5% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 26 | 31 | 36 | 41 | 46 |
|---|---|---|---|---|---|
| -7.0% | 32.3% | 37.0% | 41.2% | 44.9% | 48.3% |
| -2.0% | 39.4% | 44.4% | 48.8% | 52.7% | 56.2% |
| 3.0% | 46.5% | 51.7% | 56.3% | 60.5% | 64.2% |
| 8.0% | 53.6% | 59.1% | 63.9% | 68.3% | 72.2% |
| 13.0% | 60.7% | 66.5% | 71.5% | 76.0% | 80.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·1d ago·Positive
Coloplast A/S (CLPBY) Q3 2026 Earnings Call Transcript Coloplast A/S (CLPBY) Q3 2026 Earnings Call Transcript
View source ↗
Earnings
Tue, Nov 3(in 3 months)
Consensus estimate $0.09 per share
Typical surprise +11.1% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 18$0.10 vs $0.10beat
- Tue, May 12$0.10 vs $0.09beat
- Fri, Feb 6$0.10 vs $0.09beat
- Tue, Nov 4$0.07 vs $0.09miss
- Tue, Aug 19$0.06 vs $0.02beat
- Tue, May 6$0.06 vs $0.01beat
Estimates and results for CLPBY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.